Jesse B Fletcher1, Kirsty A Clark2, Cathy J Reback1,3. 1. Friends Research Institute, Inc., Los Angeles, CA. 2. Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT. 3. Department of Family Medicine, Center for HIV Identification, Prevention and Treatment Services, University of California Los Angeles.
Abstract
BACKGROUND: Methamphetamine use is associated with disproportionate risk of HIV infection and increased risk of depression among sexual minority men. The purpose of the study was to estimate the association between clinical depression diagnoses and sexual risk-taking among cisgender men who have sex with men (MSM) who use methamphetamine. METHOD: From March 2014 through January 2016, 286 MSM who use methamphetamine but were not seeking treatment for methamphetamine use disorder were enrolled to participate in a technology-based randomized controlled trial to reduce methamphetamine use and HIV sexual risk behaviors; participants were assessed for major depressive episodes (MDE) and persistent depressive disorder (PDD) at baseline. Multivariate clustered zero-inflated negative binomial regression analyses of condomless anal intercourse (n=282; 1,248 visits) estimated the association between this baseline diagnostic result and engagement in sexual risk-taking over time. RESULTS: Participants predominantly identified as non-white (80%), averaged 42 years of age, and reported a HIV prevalence rate of 46%. Engagement in sexual risk-taking consistently demonstrated a positive curvilinear relationship with clinical depression severity, such that, for example, participants without clinical depression (59% of the sample; coef.=1.16) and those with MDE (36% of the sample; coef.=1.45) both demonstrated elevated rates of condomless anal sex with anonymous partners relative to participants with PDD (5% of the sample; analytical reference category; both coef. p<0.05). Data also demonstrated a trend (p = 0.053) of reduced sexual risk-taking with main partners among participants diagnosed with MDE (coef.=-0.94). CONCLUSIONS: Methamphetamine use among participants in this study inverted the functional form of the relationship between depression and sexual risk among MSM observed in prior studies. Whereas low-grade depression has been associated with increased sexual risk-taking in prior samples of MSM, methamphetamine upends this relationship, such that the greatest engagement in sexual risk-taking occurred among those diagnosed with MDE at baseline. Additional research is warranted to clarify how methamphetamine influences sexual risk-taking among MSM with/without comorbid depression.
BACKGROUND: Methamphetamine use is associated with disproportionate risk of HIV infection and increased risk of depression among sexual minority men. The purpose of the study was to estimate the association between clinical depression diagnoses and sexual risk-taking among cisgender men who have sex with men (MSM) who use methamphetamine. METHOD: From March 2014 through January 2016, 286 MSM who use methamphetamine but were not seeking treatment for methamphetamine use disorder were enrolled to participate in a technology-based randomized controlled trial to reduce methamphetamine use and HIV sexual risk behaviors; participants were assessed for major depressive episodes (MDE) and persistent depressive disorder (PDD) at baseline. Multivariate clustered zero-inflated negative binomial regression analyses of condomless anal intercourse (n=282; 1,248 visits) estimated the association between this baseline diagnostic result and engagement in sexual risk-taking over time. RESULTS: Participants predominantly identified as non-white (80%), averaged 42 years of age, and reported a HIV prevalence rate of 46%. Engagement in sexual risk-taking consistently demonstrated a positive curvilinear relationship with clinical depression severity, such that, for example, participants without clinical depression (59% of the sample; coef.=1.16) and those with MDE (36% of the sample; coef.=1.45) both demonstrated elevated rates of condomless anal sex with anonymous partners relative to participants with PDD (5% of the sample; analytical reference category; both coef. p<0.05). Data also demonstrated a trend (p = 0.053) of reduced sexual risk-taking with main partners among participants diagnosed with MDE (coef.=-0.94). CONCLUSIONS: Methamphetamine use among participants in this study inverted the functional form of the relationship between depression and sexual risk among MSM observed in prior studies. Whereas low-grade depression has been associated with increased sexual risk-taking in prior samples of MSM, methamphetamine upends this relationship, such that the greatest engagement in sexual risk-taking occurred among those diagnosed with MDE at baseline. Additional research is warranted to clarify how methamphetamine influences sexual risk-taking among MSM with/without comorbid depression.
Entities:
Keywords:
HIV; MSM; depression; methamphetamine; sexual risk-taking
Authors: Michael W Plankey; David G Ostrow; Ron Stall; Christopher Cox; Xiuhong Li; James A Peck; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Brent T Mausbach; Shirley J Semple; Steffanie A Strathdee; Jim Zians; Thomas L Patterson Journal: Drug Alcohol Depend Date: 2006-12-19 Impact factor: 4.492
Authors: Susan H Eshleman; Sarah E Hudelson; Andrew D Redd; Ronald Swanstrom; San-San Ou; Xinyi Cindy Zhang; Li-Hua Ping; Estelle Piwowar-Manning; Stephen F Porcella; Matthew F Sievers; Craig A Martens; Daniel Bruno; Elena Dukhovlinova; Marybeth McCauley; Theresa Gamble; Jessica M Fogel; Devin Sabin; Thomas C Quinn; Laurence Gunde; Madalitso Maliwichi; Nehemiah Nhando; Victor Akelo; Sikhulile Moyo; Ravindre Panchia; Nagalingeswaran Kumarasamy; Nuntisa Chotirosniramit; Marineide Gonçalves de Melo; Jose Pilotto; Beatriz Grinsztejn; Kenneth Mayer; Ying Q Chen; James P Hughes; Myron S Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Lindsay E Young; Phil Schumm; Leigh Alon; Alida Bouris; Matthew Ferreira; Brandon Hill; Aditya S Khanna; Thomas W Valente; John A Schneider Journal: Clin Trials Date: 2017-09-01 Impact factor: 2.486
Authors: Kate Buchacz; Willi McFarland; Timothy A Kellogg; Lisa Loeb; Scott D Holmberg; James Dilley; Jeffrey D Klausner Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Daniel Íncera-Fernández; Manuel Gámez-Guadix; Santiago Moreno-Guillén Journal: Int J Environ Res Public Health Date: 2021-12-17 Impact factor: 3.390